Literature DB >> 20813960

Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not?

Charles N Serhan1.   

Abstract

Because inflammation is appreciated as a unifying basis of many widely occurring diseases, the mechanisms involved in its natural resolution are of considerable interest. Using contained, self-limited inflammatory exudates and a systems approach, novel lipid-derived mediators and pathways were uncovered in the resolution of inflammatory exudates. These new families of local mediators control both the duration and magnitude of acute inflammation as well as the return of the site to homeostasis in the process of catabasis. This new genus of specialized proresolving mediators (SPM) includes essential fatty acid-derived lipoxins, resolvins, protectins, and, most recently, maresins. These families were named based on their unique structures and potent stereoselective actions. The temporally initiated biosynthesis of SPM and their direct impact on leukocyte trafficking and macrophage-directed clearance mechanisms provide clear evidence that resolution is an active, programmed response at the tissue level. Moreover, SPM that possess anti-inflammatory (ie, limiting PMN infiltration) and proresolving (enhance macrophage uptake and clearance of apoptotic PMN and microbial particles) actions as well as stimulating mucosal antimicrobial responses demonstrate that anti-inflammation and proresolution are different responses of the host and novel defining properties of these molecules. The mapping of new resolution circuits has opened the possibility for understanding mechanisms that lead from acute to chronic inflammation, or to the resolution thereof, as well as to potential, resolution-based immunopharmacological therapies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20813960      PMCID: PMC2947253          DOI: 10.2353/ajpath.2010.100322

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  145 in total

1.  Total synthesis and bioactivity of resolvin E2.

Authors:  Seiji Ogawa; Daisuke Urabe; Yoshiyuki Yokokura; Hiroyuki Arai; Makoto Arita; Masayuki Inoue
Journal:  Org Lett       Date:  2009-08-20       Impact factor: 6.005

Review 2.  Resolvins: Current understanding and future potential in the control of inflammation.

Authors:  Gerard L Bannenberg
Journal:  Curr Opin Drug Discov Devel       Date:  2009-09

3.  Resolvins E1 and D1 in choroid-retinal endothelial cells and leukocytes: biosynthesis and mechanisms of anti-inflammatory actions.

Authors:  Haibin Tian; Yan Lu; Alexander M Sherwood; Dawuti Hongqian; Song Hong
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-05-14       Impact factor: 4.799

Review 4.  International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family.

Authors:  Richard D Ye; François Boulay; Ji Ming Wang; Claes Dahlgren; Craig Gerard; Marc Parmentier; Charles N Serhan; Philip M Murphy
Journal:  Pharmacol Rev       Date:  2009-06-04       Impact factor: 25.468

5.  Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators.

Authors:  Yiping Jin; Makoto Arita; Qiang Zhang; Daniel R Saban; Sunil K Chauhan; Nan Chiang; Charles N Serhan; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-04-30       Impact factor: 4.799

6.  Lipid mediator interplay: resolvin D1 attenuates inflammation evoked by glutathione-conjugated lipid peroxidation products.

Authors:  János G Filep
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

Review 7.  Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT).

Authors:  Paul M Ridker
Journal:  J Thromb Haemost       Date:  2009-07       Impact factor: 5.824

8.  Lipidomic analysis of dynamic eicosanoid responses during the induction and resolution of Lyme arthritis.

Authors:  Victoria A Blaho; Matthew W Buczynski; Charles R Brown; Edward A Dennis
Journal:  J Biol Chem       Date:  2009-06-01       Impact factor: 5.157

9.  12/15-lipoxygenase counteracts inflammation and tissue damage in arthritis.

Authors:  Gerhard Krönke; Julia Katzenbeisser; Stefan Uderhardt; Mario M Zaiss; Carina Scholtysek; Gernot Schabbauer; Alexander Zarbock; Marije I Koenders; Roland Axmann; Jochen Zwerina; Hans W Baenckler; Wim van den Berg; Reinhard E Voll; Hartmut Kühn; Leo A B Joosten; Georg Schett
Journal:  J Immunol       Date:  2009-08-12       Impact factor: 5.422

10.  Effects of low-dose aspirin on acute inflammatory responses in humans.

Authors:  Thea Morris; Melanie Stables; Adrian Hobbs; Patricia de Souza; Paul Colville-Nash; Tim Warner; Justine Newson; Geoffrey Bellingan; Derek W Gilroy
Journal:  J Immunol       Date:  2009-07-13       Impact factor: 5.422

View more
  162 in total

1.  5-Lipoxygenase-deficient mice infected with Borrelia burgdorferi develop persistent arthritis.

Authors:  Victoria A Blaho; Yan Zhang; Jennifer M Hughes-Hanks; Charles R Brown
Journal:  J Immunol       Date:  2011-01-26       Impact factor: 5.422

Review 2.  Some unmet challenges in the immunology of viral infections.

Authors:  Barry T Rouse; Aron E Lukacher
Journal:  Discov Med       Date:  2010-10       Impact factor: 2.970

Review 3.  Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology.

Authors:  Charles N Serhan
Journal:  Mol Aspects Med       Date:  2017-03-03

Review 4.  Fibroblasts in myocardial infarction: a role in inflammation and repair.

Authors:  Arti V Shinde; Nikolaos G Frangogiannis
Journal:  J Mol Cell Cardiol       Date:  2013-12-07       Impact factor: 5.000

Review 5.  CRAC channel regulation of innate immune cells in health and disease.

Authors:  Regina A Clemens; Clifford A Lowell
Journal:  Cell Calcium       Date:  2019-01-09       Impact factor: 6.817

Review 6.  Potential function of miRNAs in herpetic stromal keratitis.

Authors:  Sachin Mulik; Siddheshvar Bhela; Barry T Rouse
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-17       Impact factor: 4.799

7.  Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes.

Authors:  Bruno S Herrera; Hatice Hasturk; Alpdogan Kantarci; Marcelo O Freire; Olivia Nguyen; Shevali Kansal; Thomas E Van Dyke
Journal:  Infect Immun       Date:  2014-12-08       Impact factor: 3.441

Review 8.  Can Specialized Pro-resolving Mediators Deliver Benefit Originally Expected from Fish Oil?

Authors:  Martin D Rosenthal; Jayshil Patel; Kyle Staton; Robert G Martindale; Frederick A Moore; Gilbert R Upchurch
Journal:  Curr Gastroenterol Rep       Date:  2018-08-04

9.  Lipid and lipid mediator profiling of human synovial fluid in rheumatoid arthritis patients by means of LC-MS/MS.

Authors:  Martin Giera; Andreea Ioan-Facsinay; Rene Toes; Fei Gao; Jesmond Dalli; André M Deelder; Charles N Serhan; Oleg A Mayboroda
Journal:  Biochim Biophys Acta       Date:  2012-07-24

10.  Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles.

Authors:  Nazila Kamaly; Gabrielle Fredman; Manikandan Subramanian; Suresh Gadde; Aleksandar Pesic; Louis Cheung; Zahi Adel Fayad; Robert Langer; Ira Tabas; Omid Cameron Farokhzad
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.